RESUMO
With accumulating evidence indicating the importance of cytotoxic T lymphocytes (CTLs) in containing human immunodeficiency virus-1 (HIV-1) replication in infected individuals, strategies are being pursued to elicit virus-specific CTLs with prototype HIV-1 vaccines. Here, we report the protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys. Immune responses were elicited by DNA vaccines expressing SIVmac239 Gag and HIV-1 89.6P Env, augmented by the administration of the purified fusion protein IL-2/Ig, consisting of interleukin-2 (IL-2) and the Fc portion of immunoglobulin G (IgG), or a plasmid encoding IL-2/Ig. After SHIV-89.6P infection, sham-vaccinated monkeys developed weak CTL responses, rapid loss of CD4+ T cells, no virus-specific CD4+ T cell responses, high setpoint viral loads, significant clinical disease progression, and death in half of the animals by day 140 after challenge. In contrast, all monkeys that received the DNA vaccines augmented with IL-2/Ig were infected, but demonstrated potent secondary CTL responses, stable CD4+ T cell counts, preserved virus-specific CD4+ T cell responses, low to undetectable setpoint viral loads, and no evidence of clinical disease or mortality by day 140 after challenge.
Assuntos
Vacinas contra a AIDS/uso terapêutico , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Infecções por HIV/terapia , HIV-1 , Interleucina-2/uso terapêutico , Vacinas de DNA/uso terapêutico , Animais , Anticorpos Antivirais/sangue , Anticorpos Antivirais/imunologia , Contagem de Linfócito CD4 , Linfócitos T CD4-Positivos/imunologia , Progressão da Doença , Anticorpos Anti-HIV/sangue , Anticorpos Anti-HIV/imunologia , Infecções por HIV/imunologia , Infecções por HIV/virologia , HIV-1/genética , HIV-1/imunologia , HIV-1/fisiologia , Humanos , Interleucina-2/genética , Interleucina-2/imunologia , Ativação Linfocitária , Macaca mulatta , Testes de Neutralização , Proteínas Recombinantes de Fusão/uso terapêutico , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle , Síndrome de Imunodeficiência Adquirida dos Símios/terapia , Síndrome de Imunodeficiência Adquirida dos Símios/virologia , Vírus da Imunodeficiência Símia/genética , Vírus da Imunodeficiência Símia/imunologia , Vírus da Imunodeficiência Símia/fisiologia , Linfócitos T Citotóxicos/imunologia , Vacinação , Carga Viral , Viremia , Replicação ViralRESUMO
BACKGROUND: High functional antibody responses, establishment of immunologic memory, and unambiguous efficacy in infants suggest that an initial dose of conjugated pneumococcal polysaccharide (PnC) vaccine may be of value in a comprehensive adult immunization strategy. METHODS: We compared the immunogenicity and safety of 7-valent PnC vaccine (7vPnC) with that of 23-valent pneumococcal polysaccharide vaccine (PPV) in adults >/=70 years of age who had not been previously vaccinated with a pneumococcal vaccine. One year later, 7vPnC recipients received a booster dose of either 7vPnC (the 7vPnC/7vPnC group) or PPV (the 7vPnC/PPV group), and PPV recipients received a booster dose of 7vPnC (the PPV/7vPnC group). Immune responses were compared for each of the 7 serotypes common to both vaccines. RESULTS: Antipolysaccharide enzyme-linked immunosorbent assay antibody concentrations and opsonophagocytic assay titers to the initial dose of 7vPnC were significantly greater than those to the initial dose of PPV for 6 and 5 of 7 serotypes, respectively (P < .01 and P < .05, respectively). 7vPnC/7vPnC induced antibody responses that were similar to those after the first 7vPnC inoculation, and 7vPnC/PPV induced antibody responses that were similar to or greater than antibody responses after administration of PPV alone; PPV/7vPnC induced significantly lower antibacterial responses, compared with those induced by 7vPnC alone, for all serotypes (P < .05). CONCLUSION: In adults, an initial dose of 7vPnC is likely to elicit higher and potentially more effective levels of antipneumococcal antibodies than is PPV. In contrast with PPV, for which the induction of hyporesponsiveness was observed when used as a priming dose, 7vPnC elicits an immunological state that permits subsequent administration of 7vPnC or PPV to maintain functional antipolysaccharide antibody levels.
Assuntos
Anticorpos Antibacterianos/imunologia , Memória Imunológica , Vacinas Meningocócicas/imunologia , Vacinas Pneumocócicas/imunologia , Idoso , Anticorpos Antibacterianos/sangue , Ensaio de Imunoadsorção Enzimática , Feminino , Vacina Pneumocócica Conjugada Heptavalente , Humanos , Imunização Secundária , Masculino , Vacinas Meningocócicas/efeitos adversos , Fagocitose , Vacinas Pneumocócicas/efeitos adversosRESUMO
The crystal structure of simian immunodeficiency virus (SIV) integrase that contains in a single polypeptide the core and the C-terminal deoxyoligonucleotide binding domain has been determined at 3 A resolution with an R-value of 0.203 in the space group P2(1)2(1)2(1). Four integrase core domains and one C-terminal domain are found to be well defined in the asymmetric unit. The segment extending from residues 114 to 121 assumes the same position as seen in the integrase core domain of avian sarcoma virus as well as human immunodeficiency virus type-1 (HIV-1) crystallized in the absence of sodium cacodylate. The flexible loop in the active site, composed of residues 141-151, remains incompletely defined, but the location of the essential Glu152 residue is unambiguous. The residues from 210-218 that link the core and C-terminal domains can be traced as an extension from the core with a short gap at residues 214-215. The C(alpha) folding of the C-terminal domain is similar to the solution structure of this domain from HIV-1 integrase. However, the dimeric form seen in the NMR structure cannot exist as related by the non-crystallographic symmetry in the SIV integrase crystal. The two flexible loops of the C-terminal domain, residues 228-236 and residues 244-249, are much better fixed in the crystal structure than in the NMR structure with the former in the immediate vicinity of the flexible loop of the core domain. The interface between the two domains encompasses a solvent-exclusion area of 1500 A(2). Residues from both domains purportedly involved in DNA binding are narrowly distributed on the same face of the molecule. They include Asp64, Asp116, Glu152 and Lys159 from the core and Arg231, Leu234, Arg262, Arg263 and Lys264 from the C-terminal domain. A model for DNA binding is proposed to bridge the two domains by tethering the 228-236 loop of the C-terminal domain and the flexible loop of the core.
Assuntos
Domínio Catalítico , Proteínas de Ligação a DNA/química , Proteínas de Ligação a DNA/metabolismo , Integrases/química , Integrases/metabolismo , Vírus da Imunodeficiência Símia/enzimologia , Sequência de Aminoácidos , Vírus do Sarcoma Aviário/enzimologia , Sítios de Ligação , Cristalização , Cristalografia por Raios X , DNA/genética , DNA/metabolismo , Dimerização , Glutamina/química , Glutamina/metabolismo , Integrase de HIV/química , Modelos Moleculares , Dados de Sequência Molecular , Estrutura Quaternária de Proteína , Estrutura Terciária de Proteína , SoluçõesRESUMO
BACKGROUND: Based on the success of vaccination with pneumococcal conjugate vaccines (PCVs) in children, recent studies have focused on PCVs in adults. Data from a randomized, double-blind study comparing the immunogenicity, tolerability, and safety of the 13-valent PCV (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in PPSV23-naive adults 60-64 years of age have been published. The same study also included a cohort of adults aged 18-49 years that received open-label PCV13. The purpose of this cohort was to examine the immunogenicity, safety, and tolerability of PCV13 in adult subjects 18-49 years of age compared with adults 60-64 years of age for whom PCV13 is approved. METHODS: Adults naive to PPSV23 were grouped by age into 2 cohorts: 18-49 years (n=899; further stratified by age into 3 subgroups 18-29, 30-39, and 40-49 years) and 60-64 years (n=417). All subjects received 1 dose of PCV13. In both age groups, immunogenicity was assessed by antipneumococcal opsonophagocytic activity (OPA) geometric mean titers (GMTs) and IgG geometric mean concentrations (GMCs) 1 month after vaccination. Safety and tolerability were evaluated. RESULTS: In adults aged 18-49 years, OPA GMTs and IgG GMCs were noninferior for all 13 serotypes and statistically significantly higher for all except 1 serotype (OPA GMT) and 5 serotypes (IgG GMCs) compared with adults 60-64 years. Immune responses were highest in the youngest age subgroup (18-29 years). Local reactions and systemic events were more common in adults 18-49 years compared with 60-64 years and were self-limited. CONCLUSION: Immune responses to PCV13 are robust in adults ≥18 years of age, with highest responses observed in the youngest subgroup. Based on its safety and immunologic profile, PCV13 may serve an important therapeutic role in younger adults, particularly those with underlying medical conditions who have an increased risk of serious pneumococcal infections.
Assuntos
Vacinas Pneumocócicas/efeitos adversos , Vacinas Pneumocócicas/imunologia , Adolescente , Adulto , Anticorpos Antibacterianos/sangue , Estudos de Coortes , Método Duplo-Cego , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Feminino , Humanos , Imunoglobulina G/sangue , Masculino , Pessoa de Meia-Idade , Proteínas Opsonizantes/sangue , Fagocitose , Vacinas Pneumocócicas/administração & dosagem , Resultado do Tratamento , Adulto JovemRESUMO
The major envelope glycoprotein (gp350) of Epstein-Barr virus has been expressed and secreted in the yeast Saccharomyces cerevisiae as a 400-kDa glycoprotein. This is the first example of the secretion of such a large, heavily glycosylated heterologous protein in yeast. Since gp350 proved highly toxic to S. cerevisiae, initial cellular growth required repression of the expression of gp350. Using temperature- or galactose-inducible promoters, cells could be grown and the expression of gp350 then induced. After induction, the glycoprotein accumulated both intracellularly as well as in the culture medium. Only the most heavily glycosylated form was secreted, suggesting a role for N-linked glycans in directing secretion. The extent of O-linked glycosylation of the yeast-derived protein was similar to that of the mature viral gp350. N-linked glycosylation varied slightly depending upon culture conditions and host strain used and was more extensive than that associated with the mature viral gp350. Although there is no evidence that more than a single mRNA for the glycoprotein was expressed from the recombinant plasmid, variously sized glycoproteins accumulated in yeast at early stages after induction, probably reflecting intermediates in glycosylation. The yeast-derived glycoproteins reacted with animal and human polyclonal antibodies to gp350 as well as with a neutralizing murine monoclonal antibody to gp350, suggesting that this glycoprotein retains several epitopes of the native glycoprotein.
Assuntos
Herpesvirus Humano 4/genética , Proteínas do Envelope Viral/genética , Clonagem Molecular , Regulação da Expressão Gênica , Genes Fúngicos , Genes Virais , Glicoproteínas/biossíntese , Glicoproteínas/genética , Glicoproteínas/metabolismo , Regiões Promotoras Genéticas , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , Proteínas do Envelope Viral/biossíntese , Proteínas do Envelope Viral/metabolismoRESUMO
Eight different cell feeder layers and 2 conditioned media were compared for their ability to increase the establishment efficiency of newly formed hybridoma cells. Enhancement was noted particularly with all 3 irradiated human lung diploid fibroblasts which were tested. Hybridomas established in the presence of the feeder layers were found to be stable upon propagation even in the absence of the feeder cells. MRC-5 diploid fibroblasts are suggested as the hybridoma feeder layer cell of choice due to this cell's ease of culture and handling.
Assuntos
Hibridomas/citologia , Animais , Divisão Celular , Células Cultivadas , Chlorocebus aethiops , Meios de Cultura , Fibroblastos , Humanos , CamundongosRESUMO
A series of highly potent, structurally novel, non-nucleoside RT inhibitors has been described. Low nanomolar concentrations of 5-chloro-3-(phenylsulfonyl)-indole-2-carboxamide (1) inhibit the HIV-1 RT enzyme in vitro and HTLVIIIb viral spread in MT-4 human T-lymphoid cells. Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel. When compared to other non-nucleoside inhibitors (e.g. 15-18), 1 possesses improved inhibitory potency with respect to the wild-type RT, as well as the K103N and Y181C mutant enzymes. Additional studies within this class of inhibitors are in progress.
Assuntos
Antivirais/farmacologia , HIV-1/enzimologia , Indóis/farmacologia , Inibidores da Transcriptase Reversa , Sulfóxidos/farmacologia , Animais , Antivirais/química , Sequência de Bases , Disponibilidade Biológica , HIV/efeitos dos fármacos , Transcriptase Reversa do HIV , Indóis/química , Indóis/farmacocinética , Macaca mulatta , Dados de Sequência Molecular , Estrutura Molecular , Sulfóxidos/química , Sulfóxidos/farmacocinéticaRESUMO
A series of HIV protease inhibitors possessing a hydroxylaminepentanamide transition state isostere have been developed. Incorporation of a basic amine into the backbone of the L-685,434 (2) series provided antiviral potency combined with a highly improved pharmacokinetic profile in animal models. Guided by molecular modeling and an X-ray crystal structure of the inhibited enzyme complex, we were able to design L-735,524. This compound is potent and competitively inhibits HIV-1 PR and HIV-2 PR with Ki values of 0.52 and 3.3 nM, respectively. It also stops the spread of the HIV-1IIIb-infected MT4 lymphoid cells at concentrations of 25-50 nM. To date, numerous HIV-PR inhibitors have been reported, but few have been studied in humans because they lack acceptable oral bioavailability. L-735,524 is orally bioavailable in three animals models, using clinically acceptable formulations, and is currently in phase II human clinical trials.
Assuntos
Inibidores da Protease de HIV/síntese química , Piridinas/síntese química , Animais , Ligação Competitiva , Disponibilidade Biológica , Linhagem Celular , Cristalografia por Raios X , Cães , Desenho de Fármacos , Protease de HIV/metabolismo , Inibidores da Protease de HIV/farmacocinética , Inibidores da Protease de HIV/farmacologia , HIV-1/efeitos dos fármacos , HIV-1/enzimologia , HIV-1/crescimento & desenvolvimento , HIV-2/enzimologia , Humanos , Indinavir , Modelos Moleculares , Estrutura Molecular , Piridinas/farmacocinética , Piridinas/farmacologia , Ratos , Linfócitos T/virologiaRESUMO
By tethering of a polar hydrophilic group to the P1 or P1' substituent of a Phe-based hydroxyethylene isostere, the antiviral potency of a series of HIV protease inhibitors was improved. The optimum enhancement of anti-HIV activity was observed with the 4-morpholinylethoxy substituent. The substituent effect is consistent with a model derived from inhibitor docked in the crystal structure of the native enzyme. An X-ray crystal structure of the inhibited enzyme determined to 2.25 A verifies the modeling predictions.
Assuntos
Desenho de Fármacos , Inibidores da Protease de HIV , HIV-1/enzimologia , Inibidores de Proteases/síntese química , Sítios de Ligação , Células Cultivadas , Ensaio de Imunoadsorção Enzimática , Protease de HIV/metabolismo , HIV-1/efeitos dos fármacos , Humanos , Modelos Moleculares , Morfolinas/química , Morfolinas/farmacologia , Peptídeos/química , Peptídeos/farmacologia , Inibidores de Proteases/farmacologia , Vírus da Imunodeficiência Símia/efeitos dos fármacos , Difração de Raios XRESUMO
Recent results from human clinical trials have established the critical role of HIV protease inhibitors in the treatment of acquired immune-deficiency syndrome (AIDS). However, the emergence of viral resistance, demanding treatment protocols, and adverse side effects have exposed the urgent need for a second generation of HIV protease inhibitors. The continued exploration of our hydroxylaminepentanamide (HAPA) transition-state isostere series of HIV protease inhibitors, which initially resulted in the identification of Crixivan (indinavir sulfate, MK-639, L-735,524), has now yielded MK-944a (L-756,423). This compound is potent, is selective, and competitively inhibits HIV-1 PR with a K(i) value of 0.049 nM. It stops the spread of the HIV(IIIb)-infected MT4 lymphoid cells at 25.0-50.0 nM, even in the presence of alpha(1) acid glycoprotein, human serum albumin, normal human serum, or fetal bovine serum. MK-944a has a longer half-life in several animal models (rats, dogs, and monkeys) than indinavir sulfate and is currently in advanced human clinical trials.
Assuntos
Antivirais/síntese química , Inibidores da Protease de HIV/síntese química , HIV-1/efeitos dos fármacos , Indanos/síntese química , Piperazinas/síntese química , Animais , Antivirais/química , Antivirais/farmacocinética , Antivirais/farmacologia , Bovinos , Técnicas de Cultura de Células , Cães , Avaliação Pré-Clínica de Medicamentos , Resistência Microbiana a Medicamentos , Inibidores da Protease de HIV/química , Inibidores da Protease de HIV/farmacocinética , Inibidores da Protease de HIV/farmacologia , Haplorrinos , Humanos , Indanos/química , Indanos/farmacocinética , Indanos/farmacologia , Masculino , Piperazinas/química , Piperazinas/farmacocinética , Piperazinas/farmacologia , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Relação Estrutura-Atividade , Cálculos Urinários/induzido quimicamente , Cálculos Urinários/urinaRESUMO
Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 (HIV-1) was used to immunize chimpanzees. The animals developed high titers of antibodies to p55 as well as to the p24 and p17 mature cleavage products of the core precursor. Virus-neutralizing antibodies were not elicited. The induced immune responses did not prevent establishment of HIV-1 infection following challenge of one immunized chimpanzee with live virus.
Assuntos
Produtos do Gene gag/imunologia , Anticorpos Anti-HIV/biossíntese , Antígenos HIV/imunologia , Infecções por HIV/imunologia , Precursores de Proteínas/imunologia , Animais , Produtos do Gene gag/genética , Proteína do Núcleo p24 do HIV , Proteína gp41 do Envelope de HIV/imunologia , Infecções por HIV/prevenção & controle , Imunização , Testes de Neutralização , Pan troglodytes , Precursores de Proteínas/genética , Proteínas Recombinantes/imunologia , Saccharomyces cerevisiae/genética , Proteínas do Core Viral/imunologiaRESUMO
The CD4-binding domain of human immunodeficiency virus type 1 (HIV-1) gp120 elicits antibodies that are present in infected human sera. Monoclonal antibodies that recognize the HIV-1 gp120 CD4-binding domain have been isolated. Some of these antibodies can neutralize laboratory-adapted strains of HIV-1 and probably mediate neutralization by interfering with virus binding to its cellular CD4 receptor. However, most anti-CD4 binding domain antibodies do not neutralize primary HIV-1 isolates. We used primary HIV-1 isolates in an infectivity reduction assay to test the uniquely derived anti-CD4 binding domain recombinant human monoclonal antibody, IgG1b12. All of the tested HIV-1 isolates were neutralized by this antibody. Additional studies indicated that neutralization of a primary isolate with MAb IgG1b12 did not require continuous exposure of human peripheral blood mononuclear cell cultures to the antibody. Finally, a complete IgG1 molecule of an in vitro-selected b12 FAb mutant with a > 400-fold increase in affinity was assembled, expressed in mammalian cells, and evaluated in the infectivity reduction assay in comparative studies with the parent IgG1b12 antibody. The mutant did not retain the level of primary isolate neutralization potency that was a property of the parent molecule. Thus, we confirm that recombinant IgG1b12 has a unique specificity, and that it can neutralize all primary isolates tested in human PBMC cultures in vitro.
Assuntos
Anticorpos Monoclonais/imunologia , Proteína gp120 do Envelope de HIV/genética , Proteína gp120 do Envelope de HIV/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , Imunoglobulina G/imunologia , Proteínas Recombinantes/imunologia , Antígenos CD4/imunologia , Células Cultivadas , Humanos , Fragmentos Fab das Imunoglobulinas/genética , Cadeias Pesadas de Imunoglobulinas/genética , Cadeias Leves de Imunoglobulina/genética , Íntrons , Leucócitos Mononucleares , Testes de Neutralização , Sinais Direcionadores de Proteínas/genética , Sinais Direcionadores de Proteínas/imunologiaRESUMO
The nonnucleoside reverse transcriptase (RT) inhibitors are structurally diverse compounds that are specific inhibitors of the human immunodeficiency virus type 1 RT enzyme. The compounds are largely functionally identical and bind to a common site in the enzyme. HIV-1 variants that exhibit reduced susceptibility to these inhibitors have been derived in cell culture and, more recently, from HIV-1-infected patients undergoing experimental therapy. The variants express amino acid substitutions at RT positions that apparently interact directly with the inhibitors. Effects of specific substitutions at these positions vary among the compounds, suggesting subtle differences in how the compounds physically interact with the enzyme.
Assuntos
Antivirais/farmacologia , Variação Genética , HIV-1/efeitos dos fármacos , Inibidores da Transcriptase Reversa , Benzodiazepinas/farmacologia , Benzoxazóis/farmacologia , Ensaios Clínicos como Assunto , Resistência Microbiana a Medicamentos/genética , Infecções por HIV/tratamento farmacológico , Transcriptase Reversa do HIV , HIV-1/genética , Humanos , Imidazóis/farmacologia , Nevirapina , Piridinas/farmacologia , Piridonas/farmacologia , DNA Polimerase Dirigida por RNA/genéticaRESUMO
Carrier protein conjugates of five synthetic peptides containing amino acid sequences specific to capsid proteins VP1 and VP2 of poliovirus type 1 were tested for their abilities to elicit an immune response in the presence of either of two adjuvants and in several animal species. Freund's adjuvant induced significantly higher level anti-peptide antibody titers than A1(OH)3. However, no difference was noted between the two adjuvants in their abilities to aid in the induction of cross-reactive virus neutralizing antibody. The latter antibody was more readily produced by rabbits than by guinea pigs in spite of equivalent anti-peptide titers. Rats failed to produce neutralizing antibodies and their anti-peptide antibody levels were generally lower. The significance of these results for studies involving the development of synthetic peptide immunogens is discussed.
Assuntos
Anticorpos Antivirais/biossíntese , Vacina Antipólio de Vírus Inativado/imunologia , Poliovirus/imunologia , Adjuvantes Imunológicos , Animais , Cobaias , Fragmentos de Peptídeos/síntese química , Fragmentos de Peptídeos/imunologia , Coelhos , Ratos , Proteínas Virais/imunologiaRESUMO
A microtiter cell-culture assay is described for measuring neutralizing antibody activity directed against the human immunodeficiency virus (HIV). The assay relies upon inhibition of HIV-mediated cell killing of infected MT-4 lymphoid cells. The assay exhibits comparable sensitivity to two other methods used for such measurements, is relatively rapid, may be adapted for screening large numbers of samples and involves minimal handling of infectious virus.
Assuntos
HIV/isolamento & purificação , Anticorpos Antivirais/análise , Linhagem Celular , Sobrevivência Celular , Corantes , Anticorpos Anti-HIV , Testes de Neutralização/métodos , Sais de Tetrazólio , TiazóisRESUMO
The synthesis of the hepatitis B surface antigen (HBsAG) in cells of Saccharomyces cerevisiae and its subsequent isolation, purification and analysis is described. The final, purified HBsAg particle exhibits close structural and biochemical similarities to particles derived from the plasma of chronically infected humans. Particles of yeast and human origin have been found, by chimpanzee efficacy studies and by various in vitro analyses, to be immunologically equivalent. The antigenic expression of a determinant-specific epitopes, as measured by antibody binding to synthetic peptides, has also been shown to be equivalent.
Assuntos
Antígenos de Superfície da Hepatite B/imunologia , Vírus da Hepatite B/genética , Vacinas contra Hepatite Viral/imunologia , Animais , DNA Recombinante , Epitopos/imunologia , Genes Virais , Antígenos de Superfície da Hepatite B/análise , Antígenos de Superfície da Hepatite B/genética , Antígenos de Superfície da Hepatite B/isolamento & purificação , Vacinas contra Hepatite B , Vírus da Hepatite B/imunologia , Humanos , Microscopia Eletrônica , Pan troglodytes , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/imunologia , Saccharomyces cerevisiae/genética , Vacinas contra Hepatite Viral/análise , Vacinas contra Hepatite Viral/isolamento & purificaçãoRESUMO
L-735,524 is a potent inhibitor of the HIV-1 protease. In cell culture, the compound interferes with virus replication by causing production of noninfectious immature viral particles containing an unprocessed gag-pol polyprotein. Initial human clinical studies demonstrated that treatment with the inhibitor caused circulating viral levels to decline and this decline was associated with increases in the CD4 count of varying magnitude. However, in most patients, antiviral activity is lost as viral variants with reduced susceptibility to the inhibitor are selected. The resistant phenotype appears to require an amino acid substitution at protease codon 82. However, this amino acid alteration alone is insufficient for expression of the resistance phenotype. Co-expression of various additional alterations seems to be required, but the nature of these additional substitutions differs among resistant isolates. HIV-1 variants, cross-resistant to a panel of structurally diverse protease inhibitors, were isolated from patients following prolonged L-735,524 therapy.
Assuntos
Antivirais/farmacologia , Inibidores da Protease de HIV/farmacologia , HIV-1/efeitos dos fármacos , Piridinas/farmacologia , Resistência Microbiana a Medicamentos , HIV-1/genética , Humanos , IndinavirRESUMO
Different cell culture media were compared for their ability to support and promote the growth of stable hybridoma cell lines derived from three commonly used parental murine myelomas. Supplemented Dulbecco's modified Eagle's media (DMEM) and RPMI 1640 media were studied. The DMEM-based media were found to support greater numbers of cells for longer time periods than were the RPMI 1640-based media. Aminopterin supplemented medium was shown to be significantly less effective in supporting hybridoma reproduction and viability than medium without aminopterin. Antibody levels were directly related to cell concentration and viability regardless of the medium used for the hybridoma culture. An optimally formulated DMEM-based medium is suggested as the medium of choice for hybridoma propagation and maintenance.
Assuntos
Meios de Cultura , Hibridomas , Animais , Formação de Anticorpos , Divisão Celular , Sobrevivência Celular , Congelamento , Hibridomas/citologia , Hibridomas/imunologia , Camundongos , Preservação Biológica , Fatores de TempoRESUMO
A computerized system for the management of hybridoma cell growth data using voice input is described. The system permits the storage, retrieval, and analysis of data for hybridoma cells secreting monoclonal antibodies. It consists of a local system residing on a professional computer interfaced to a mainframe processing system. The local system uses voice-input to facilitate data entry while data flagged for retention is stored on the mainframe. The system permits the investigator to monitor thousands of candidate cell lines until selection for specific antibody production is completed. All record-keeping aspects of hybridoma cell culture from establishment through freezing and storage of selected cell lines can be accomplished by personnel without computer expertise.